{"id":49789,"date":"2022-10-19T12:02:11","date_gmt":"2022-10-19T10:02:11","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\/"},"modified":"2022-10-19T12:02:11","modified_gmt":"2022-10-19T10:02:11","slug":"triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\/","title":{"rendered":"Triumvira Immunologics Announces Expansion of Cell Therapy Manufacturing Capabilities to Facility in South San Francisco"},"content":{"rendered":"
\n

AUSTIN, Texas, SOUTH SAN FRANCISCO & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics<\/a> (\u201cTriumvira\u201d), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer, today announced a multi-year agreement with AmplifyBio to use its facilities in South San Francisco, Calif. for Triumvira to manufacture its own cell therapy candidates within the company\u2019s pipeline.\n<\/p>\n

<\/a><\/p>\n

\nThe advanced research and manufacturing space features an FDA-compliant GMP facility and will be staffed by Triumvira technical operations experts in cell therapy manufacturing, with plans for additional personnel in the coming years. Triumvira expects the facility to be fully operational in 2023.\n<\/p>\n

\n\u201cTriumvira\u2019s modular TAC manufacturing process offers the ability to integrate quickly and effectively into this new facility as well as potentially into additional GMP spaces,\u201d said Donna Rill, Chief Technology Officer at Triumvira. \u201cOur newly expanded manufacturing team also brings the deep technical expertise required to bring forward TAC T cell therapies as a potential new class of medicines.\u201d\n<\/p>\n

\nThe South San Francisco facility is Triumvira\u2019s second manufacturing location and is expected to provide supplemental manufacturing capacity to meet the demand for its ongoing clinical research studies. In 2018, Triumvira entered into a strategic relationship with C3i Center Inc. (C3i) to manufacture cell therapy candidates for its clinical trials at C3i\u2019s state-of-the art GMP facility, with capabilities to manufacture cell therapies from process development to commercialization, located in Montreal.\n<\/p>\n

\nOnce operational, the South San Francisco facility will manufacture TAC01-HER2, which is currently in a Phase 1\/2 trial for solid tumors, and manufacture additional candidates for subsequent clinical studies. Manufacturing of Triumvira\u2019s second most advanced candidate, TAC-Claudin 18.2 \u2013 in preclinical development for the treatment of gastric cancer \u2013 will start at C3i in 2023.\n<\/p>\n

\n\u201cWe are excited to expand our manufacturing footprint in the U.S., which is an important component of our overall strategic growth plan and accelerates our ability to launch new programs into the clinic over the next few years,\u201d said Paul Lammers, M.D., M.Sc., President and CEO of Triumvira. \u201cSouth San Francisco is home to the largest biotech cluster in the world and we look forward to establishing our presence among the world\u2019s most prolific biotech companies, as well as gaining access to the highly-skilled talent in the area.\u201d\n<\/p>\n

\nAbout Triumvira Immunologics<\/b>\n<\/p>\n

\nTriumvira is a clinical-stage company developing a best-in-class, rationally designed cell therapy platform based on its proprietary T cell Antigen Coupler (TAC) technology. Its lead candidate, TAC01-HER2, is being evaluated in an ongoing Phase 1\/2 trial for HER2-positive solid tumors with positive initial safety and efficacy data to-date. Triumvira\u2019s pipeline includes other compelling pre-clinical solid tumor programs targeting Claudin 18.2, GUCY2C and GPC3, among others, with anticipated IND filings over the next few years. Supporting the pipeline has been an industrialized, drug-like, approach to manufacturing, including the first-mover adoption of the Lonza Cocoon\u00ae Platform that has yielded high quality product and a very high manufacturing success rate at a lower cost compared to other autologous approaches. Building on the proof-of-concept of its clinical-stage autologous TAC01-HER2 program, Triumvira is continuing to develop and advance its gamma delta allogeneic pipeline with IND filings anticipated over the next three years.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Relations:<\/b>
Stephanie Carrington
\n
ICR Westwicke
\n
Stephanie.Carrington@westwicke.com<\/a>
646-277-1282<\/p>\n

Media Relations:<\/b>
Karen Chase
\n
ICR Westwicke
\n
Karen.Chase@westwicke.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

AUSTIN, Texas, SOUTH SAN FRANCISCO & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics (\u201cTriumvira\u201d), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer, today announced a multi-year agreement with AmplifyBio to use its facilities in South San Francisco, Calif. for Triumvira to … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49789","6":"format-standard","7":"category-industry"},"yoast_head":"\nTriumvira Immunologics Announces Expansion of Cell Therapy Manufacturing Capabilities to Facility in South San Francisco - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Triumvira Immunologics Announces Expansion of Cell Therapy Manufacturing Capabilities to Facility in South San Francisco - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"AUSTIN, Texas, SOUTH SAN FRANCISCO & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics (\u201cTriumvira\u201d), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer, today announced a multi-year agreement with AmplifyBio to use its facilities in South San Francisco, Calif. for Triumvira to ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-19T10:02:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221019005434\/en\/1606821\/21\/Triumvira_Logo_2021.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Triumvira Immunologics Announces Expansion of Cell Therapy Manufacturing Capabilities to Facility in South San Francisco\",\"datePublished\":\"2022-10-19T10:02:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\\\/\"},\"wordCount\":580,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221019005434\\\/en\\\/1606821\\\/21\\\/Triumvira_Logo_2021.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\\\/\",\"name\":\"Triumvira Immunologics Announces Expansion of Cell Therapy Manufacturing Capabilities to Facility in South San Francisco - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221019005434\\\/en\\\/1606821\\\/21\\\/Triumvira_Logo_2021.jpg\",\"datePublished\":\"2022-10-19T10:02:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221019005434\\\/en\\\/1606821\\\/21\\\/Triumvira_Logo_2021.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221019005434\\\/en\\\/1606821\\\/21\\\/Triumvira_Logo_2021.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Triumvira Immunologics Announces Expansion of Cell Therapy Manufacturing Capabilities to Facility in South San Francisco\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Triumvira Immunologics Announces Expansion of Cell Therapy Manufacturing Capabilities to Facility in South San Francisco - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\/","og_locale":"en_US","og_type":"article","og_title":"Triumvira Immunologics Announces Expansion of Cell Therapy Manufacturing Capabilities to Facility in South San Francisco - Pharma Trend","og_description":"AUSTIN, Texas, SOUTH SAN FRANCISCO & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics (\u201cTriumvira\u201d), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer, today announced a multi-year agreement with AmplifyBio to use its facilities in South San Francisco, Calif. for Triumvira to ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-19T10:02:11+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221019005434\/en\/1606821\/21\/Triumvira_Logo_2021.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Triumvira Immunologics Announces Expansion of Cell Therapy Manufacturing Capabilities to Facility in South San Francisco","datePublished":"2022-10-19T10:02:11+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\/"},"wordCount":580,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221019005434\/en\/1606821\/21\/Triumvira_Logo_2021.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\/","url":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\/","name":"Triumvira Immunologics Announces Expansion of Cell Therapy Manufacturing Capabilities to Facility in South San Francisco - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221019005434\/en\/1606821\/21\/Triumvira_Logo_2021.jpg","datePublished":"2022-10-19T10:02:11+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221019005434\/en\/1606821\/21\/Triumvira_Logo_2021.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221019005434\/en\/1606821\/21\/Triumvira_Logo_2021.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/triumvira-immunologics-announces-expansion-of-cell-therapy-manufacturing-capabilities-to-facility-in-south-san-francisco\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Triumvira Immunologics Announces Expansion of Cell Therapy Manufacturing Capabilities to Facility in South San Francisco"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49789"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49789\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}